The indole-3-carbinol cyclic tetrameric derivative CTet synergizes with cisplatin and doxorubicin in triple-negative breast cancer cell lines

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1867-1872

  De Santi, Mauro ^a   Galluzzi, Luca ^a   Duranti, Andrea ^a   Magnani, Mauro ^a   Brandi, Giorgio ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Autophagy; BT 20 cells; I3C derivative CTet; MAP1LC3B; MDA MB 231; Synergy; Triple negative breast cancer

Indexed keywords

3 INDOLEMETHANOL; CISPLATIN; DOXORUBICIN; MICROTUBULE ASSOCIATED PROTEIN 1;

ARTICLE; AUTOPHAGY; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

AUTOPHAGY; BT-20 CELLS; I3C DERIVATIVE CTET; MAP1LC3B; MDA-MB-231; SYNERGY; TRIPLE-NEGATIVE BREAST CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; INDOLES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED;

EID: 84878173046     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Oakman C, Viale G and Di Leo A: Management of triple negative breast cancer. Breast 19(5): 312-321, 2010.
2. Dawood S: Triple-negative breast cancer: Epidemiology and management options. Drugs 70(17): 2247-2258, 2010.
3. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S: Treatment of triplenegative breast cancer (TNBC): Current options and future perspectives. Cancer Treat Rev 36(Suppl 3):S80-86, 2010.
4. Aggarwal BB and Ichikawa H: Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4 (9): 1201-1215, 2005. (Pubitemid 41365390)
5. Weng JR, Tsai CH, Kulp SK and Chen CS: Indole-3-carbinol as a chemopreventive and anticancer agent. Cancer Lett 262(2): 153-163, 2008.
6. Brandi G, Paiardini M, Cervasi B, Fiorucci C, Filippone P, De Marco C, Zaffaroni N and Magnani M: A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogendependent and estrogen-independent breast cancer cell lines. Cancer Res 63(14): 4028-4036, 2003. (Pubitemid 36917923)
7. Lucarini S, De Santi M, Antonietti F, Brandi G, Diamantini G, Fraternale A, Paoletti MF, Tontini A, Magnani M and Duranti A: Synthesis and biological evaluation of a γ-cyclodextrin-based formulation of the anticancer agent 5,6,11,12,17,18,23,24- octahydrocyclododeca[1,2-b:4,5-b':7,8-b'':10,11-b'''] tetraindole (CTet). Molecules 15: 4085-4093, 2010.
8. De Santi M, Galluzzi L, Lucarini S, Paoletti MF, Fraternale A, Duranti A, De Marco C, Fanelli M, Zaffaroni N, Brandi G and Magnani M: The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. Breast Cancer Res 13(2): R33, 2011.
9. Galluzzi L, De Santi M, Crinelli R, De Marco C, Zaffaroni N, Duranti A, Brandi G and Magnani M: Induction of endoplasmic reticulum stress response by the indole-3-carbinol cyclic tetrameric derivative CTet in human breast cancer cell lines. PLoS One 7(8): e43249, 2012.
10. Chou TC and Talalay P: Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
11. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3): 621-681, 2006.
12. Tam VH, Schilling AN, Lewis RE, Melnick DA and Boucher AN: Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 48(11): 4315-4321, 2004. (Pubitemid 39434892)
13. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61(2): 439-444, 2001. (Pubitemid 32128593)
14. Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2): 440-446, 2010.
15. Greco WR, Park HS and Rustum YM: Application of a new approach for the quantitation of drug synergism to the combination of cis- diamminedichloroplatinum and 1-β-Darabinofuranosylcytosine. Cancer Res 50(17): 5318-5327, 1990. (Pubitemid 20302982)
16. Greco WR, Bravo G and Parsons JC: The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 47(2): 331-385, 1995.
17. Boucher AN and Tam VH: Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis 55(4): 319-325, 2006. (Pubitemid 44128726)
18. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL and Graham CH: Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor- 1 activity. Mol Cancer Ther 7(7): 1961-1973, 2008.
19. Steeves MA, Dorsey FC and Cleveland JL: Targeting the autophagy pathway for cancer chemoprevention. Curr Opin Cell Biol 22 (2): 218-225, 2010.